101 related articles for article (PubMed ID: 26886689)
1. Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor.
Assal A; Dong B; Khan H; Medavarapu R; Shastri A; Pradhan K; Friedman E; Mantzaris I; Janakiram M; Battini R; Kornblum N; Yu Y; Verma A; Braunschweig I; Derman O
Leuk Lymphoma; 2016 Oct; 57(10):2452-5. PubMed ID: 26886689
[No Abstract] [Full Text] [Related]
2. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.
Wang W; Cortes JE; Lin P; Khoury JD; Ai D; Tang Z; Tang G; Jorgensen JL; Medeiros LJ; Hu S
Leukemia; 2015 Nov; 29(11):2263-6. PubMed ID: 25931274
[No Abstract] [Full Text] [Related]
3. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Wang W; Cortes JE; Liu E; Miranda RN; Zhao C; Yuan J; Lu X; Yang W; Ameri MD; Kantarjian HM; Medeiros LJ; Hu S
Blood Cancer J; 2016 May; 6(5):e418. PubMed ID: 27152845
[No Abstract] [Full Text] [Related]
4. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival.
Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Willemsen SP; Valk PJM; Visser O; Cornelissen JJ; Westerweel PE
Haematologica; 2017 Dec; 102(12):e486-e489. PubMed ID: 28860340
[No Abstract] [Full Text] [Related]
5. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.
Wang W; Chen Z; Hu Z; Yin CC; Li S; Bai S; Bueso-Ramos CE; Medeiros LJ; Hu S
Blood Cancer J; 2016 Nov; 6(11):e490. PubMed ID: 27813536
[No Abstract] [Full Text] [Related]
6. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Pagnano KB; Bendit I; Boquimpani C; De Souza CA; Miranda EC; Zalcberg I; Larripa I; Nardinelli L; Silveira RA; Fogliatto L; Spector N; Funke V; Pasquini R; Hungria V; Chiattone CS; Clementino N; Conchon M; Moiraghi EB; Lopez JL; Pavlovsky C; Pavlovsky MA; Cervera EE; Meillon LA; Simões B; Hamerschlak N; Bozzano AH; Mayta E; Cortes J; Bengió RM;
Cancer Invest; 2015; 33(9):451-8. PubMed ID: 26288116
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
10. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Gong Z; Zheng L; Tang Z; Chen Z; Wang W; Bai S; Tang G; Medeiros LJ; Hu S
Ann Hematol; 2017 Mar; 96(3):501-504. PubMed ID: 27915425
[No Abstract] [Full Text] [Related]
11. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
[No Abstract] [Full Text] [Related]
12. Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population-based study.
Jamy O; Godby R; Sarmad R; Costa LJ
Am J Hematol; 2021 Jul; 96(7):E265-E268. PubMed ID: 33864684
[No Abstract] [Full Text] [Related]
13. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
14. [Can chronic myeloid leukemia be cured by tyrosine kinase inhibitor?].
Li MQ; Liu ZG
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):725-8. PubMed ID: 23978030
[No Abstract] [Full Text] [Related]
15. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Quintás-Cardama A; Kantarjian H; Cortes J
N Engl J Med; 2007 Oct; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
[No Abstract] [Full Text] [Related]
16. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
[No Abstract] [Full Text] [Related]
17. Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia.
Machado-Alba JE; Machado-Duque ME
Int J Clin Pharm; 2017 Aug; 39(4):851-859. PubMed ID: 28508322
[TBL] [Abstract][Full Text] [Related]
18. [III. Chronic myeloid leukemia-effectiveness of second generation tyrosine kinase inhibitors for first line treatment of chronic myeloid leukemia-].
Takahashi N
Gan To Kagaku Ryoho; 2012 May; 39(5):743-6. PubMed ID: 22701901
[No Abstract] [Full Text] [Related]
19. Extranodal marginal zone lymphoma arising in a patient with chronic myelogenous leukemia on long-term tyrosine kinase inhibitors.
Xu X; Hassan A
Leuk Lymphoma; 2014 Mar; 55(3):715-7. PubMed ID: 23741976
[No Abstract] [Full Text] [Related]
20. Increased values of the circulating PDGFβ sustains the "withdrawal syndrome" after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia.
Galimberti S; Fontanelli G; Barsotti S; Ricci F; Guerrini F; Baratè C
Blood Cells Mol Dis; 2015 Oct; 55(3):211-2. PubMed ID: 26227847
[No Abstract] [Full Text] [Related]
[Next] [New Search]
